Can-Fite BioPharma Ltd. CANF

Company Overview

Can-Fite BioPharma Ltd. is an Israel-based clinical-stage biotechnology company focused on developing small-molecule therapeutics that target the A3 adenosine receptor (A3AR) and related adenosine receptor pathways. The company operates within the biopharmaceutical and drug development industries, with a primary emphasis on inflammatory diseases, liver disorders, oncology, and metabolic conditions. Its lead drug candidates include Piclidenoson for psoriasis and other inflammatory conditions, Namodenoson for liver diseases and hepatocellular carcinoma, and CF602 for erectile dysfunction. The company’s revenue profile has historically been driven primarily by licensing agreements, collaboration arrangements, and capital market financing rather than commercialized product sales, as its therapeutic candidates remain in clinical development.

Can-Fite was founded in 1994 and is headquartered in Petah Tikva, Israel. The company was established around research conducted on adenosine receptor biology and has evolved into a clinical-stage biotechnology enterprise with multiple investigational compounds targeting diseases with significant unmet medical need. Can-Fite has positioned itself around the selective targeting of A3AR, which the company states is highly expressed in pathological inflammatory and cancer cells while demonstrating lower expression in normal tissues. This receptor-focused platform has formed the basis of its intellectual property portfolio and clinical development strategy.

Business Operations

Can-Fite conducts operations primarily through its biotechnology research and clinical development activities. The company’s core business units revolve around the advancement of its proprietary drug candidates, particularly Piclidenoson, Namodenoson, and CF602. Revenue generation has historically come from milestone payments, licensing arrangements, research collaborations, and equity financing activities disclosed in public filings, including SEC filings and annual reports. Clinical trials have been conducted across multiple jurisdictions, including the United States, Europe, and Asia, with regulatory engagement involving agencies such as the U.S. Food and Drug Administration and other international health authorities.

The company maintains intellectual property related to A3 adenosine receptor agonists and associated therapeutic applications. Can-Fite has entered into regional licensing and commercialization agreements with pharmaceutical partners in territories including Asia and other international markets. Public disclosures identify collaborations and licensing arrangements involving companies such as Cipher Pharmaceuticals, Kyongbo Pharm, and other regional pharmaceutical entities for development and commercialization rights. The company does not currently operate large-scale manufacturing infrastructure and instead relies on contract research organizations and external manufacturing partners for portions of clinical development and production activities.

Strategic Position & Investments

Can-Fite’s strategic direction centers on advancing late-stage clinical development programs while seeking regional licensing partnerships to offset development costs and expand market reach. The company has emphasized indications with high unmet medical need and orphan or specialty-drug potential, particularly in liver disease and inflammatory disorders. Namodenoson has been developed for hepatocellular carcinoma and non-alcoholic steatohepatitis-related conditions, while Piclidenoson has remained a central asset in psoriasis and inflammatory disease studies. The company has also explored broader applications of A3AR-targeted therapies in oncology and metabolic disease settings.

The company’s investment priorities have focused on clinical trials, intellectual property expansion, and strategic licensing relationships rather than large-scale acquisitions. Public disclosures indicate continued investment in regulatory advancement and international commercialization infrastructure through partnerships rather than direct operational expansion. Can-Fite has also highlighted research involving biomarker-driven patient selection and receptor-expression targeting as part of its therapeutic strategy. Data regarding the long-term commercial viability of its pipeline remains inconclusive based on available public sources, as none of the company’s lead candidates had achieved broad regulatory approval as of recent public disclosures.

Geographic Footprint

Can-Fite is headquartered in Petah Tikva, Israel, and maintains a global clinical and commercial partnership footprint spanning North America, Europe, and Asia-Pacific regions. The company’s shares trade on the NYSE American exchange under the ticker CANF and also trade on the Tel Aviv Stock Exchange, providing access to both U.S. and Israeli capital markets. Clinical development activities have involved multinational trial sites and international regulatory interactions.

The company has established licensing and distribution relationships in several international markets, particularly in South Korea, Canada, and parts of Asia. Through these partnerships, Can-Fite seeks to leverage regional pharmaceutical expertise for commercialization and regulatory execution. Its operational influence internationally is primarily tied to licensing arrangements, clinical trial management, and intellectual property deployment rather than direct manufacturing or large-scale commercial infrastructure ownership.

Leadership & Governance

Can-Fite BioPharma was founded by Prof. Pnina Fishman, who has played a central role in the scientific and strategic development of the company and its A3 adenosine receptor platform. Leadership communications and public filings emphasize a strategy focused on receptor-targeted therapeutics, global licensing partnerships, and advancement of clinical-stage assets through regulatory pathways. Governance activities are overseen through a board structure consistent with publicly traded biotechnology companies listed in both Israel and the United States.

Key executives identified in recent public disclosures include:

• Prof. Pnina Fishman – Executive Chairperson
• Motti Farbstein – Chief Executive Officer
• Dr. Sari Fishman – Vice President Business Development
• Hadasit Yardeni – Chief Operating Officer
• Maya Kadosh – Chief Financial Officer

The company’s leadership strategy has consistently emphasized capital-efficient drug development, international collaboration agreements, and continued expansion of its intellectual property portfolio related to adenosine receptor therapeutics.